// App-Quantinova.ai

406 : FOLFERA: A randomized phase II study of irinotecan, 5-fluorouracil (5-FU), and folinic acid (FOLFIRI) with or without addition of the endothelin receptor antagonist (ETAR) zibotentan in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy.

Researchers

Presenter

  • Anne L. Thomas

Principal Investigators

  • Angela Claire Casbard

Medical Centers

  • Wales Cancer Trials Unit, Cardiff University, Cardiff, United Kingdom

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Adrucil injection

  • L-leucovorin

  • Oxaliplatin

  • Irinotecan

  • Zibotentan

  • FOLFIRI

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved